Literature DB >> 7608322

Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration.

H Derendorf1, G Hochhaus, S Rohatagi, H Möllmann, J Barth, H Sourgens, M Erdmann.   

Abstract

The pharmacokinetics of triamcinolone acetonide were studied after intravenous (2 mg), oral (5 mg), and inhaled (2 mg) administration. Triamcinolone acetonide concentrations were measured in plasma by high-performance liquid chromatography/radioimmunoassay. After intravenous administration, triamcinolone acetonide was eliminated with a total body clearance of 37 L/h and a half-life of 2.0 hours. The volume of distribution was 103 L, and oral bioavailability averaged 23%. Absorption was rapid, achieving maximum triamcinolone acetonide levels of 10.5 ng/mL after 1 hour. After inhalation, bioavailability averaged 22% with maximum levels of 2.0 ng/mL observed after 2.1 hours. The resulting systemic levels for all three treatments caused a significant decrease in the number of lymphocytes in blood.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608322     DOI: 10.1002/j.1552-4604.1995.tb04064.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  16 in total

Review 1.  Inhaled steroids for COPD?

Authors:  A E Tattersfield; T W Harrison
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 2.  Methods to identify drug deposition in the lungs following inhalation.

Authors:  H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

3.  A pharmacokinetic simulation tool for inhaled corticosteroids.

Authors:  Benjamin Weber; Guenther Hochhaus
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

4.  A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids.

Authors:  B Meibohm; G Hochhaus; H Möllmann; J Barth; M Wagner; M Krieg; R Stöckmann; H Derendorf
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

5.  Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.

Authors:  P T Daley-Yates; A C Price; J R Sisson; A Pereira; N Dallow
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 6.  Safety of inhaled and intranasal corticosteroids: lessons for the new millennium.

Authors:  B J Lipworth; C M Jackson
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

7.  Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis.

Authors:  Daniel K C Lee; Fiona M Robb; Erika J Sims; Graeme P Currie; Lesley C McFarlane; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2003-03       Impact factor: 4.335

8.  Analysis of a pitfall in congenital adrenal hyperplasia newborn screening: evidence of maternal use of corticoids detected on dried blood spot.

Authors:  Muriel Houang; Thao Nguyen-Khoa; Thibaut Eguether; Bettina Ribault; Séverine Brabant; Michel Polak; Irène Netchine; Antonin Lamazière
Journal:  Endocr Connect       Date:  2022-06-15       Impact factor: 3.221

Review 9.  Inhaled corticosteroids: potency, dose equivalence and therapeutic index.

Authors:  Peter T Daley-Yates
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

10.  Can intramuscular corticosteroid injection cause nonarteritic anterior ischemic optic neuropathy?

Authors:  Berker Bakbak; Banu Turgut Ozturk; Sansal Gedik; Bengu Ekinci Koktekir; Saban Gonul
Journal:  Clin Ophthalmol       Date:  2013-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.